Why the study?
Current risk stratification methods are imperfect for identifying patients at high risk for adverse clinical events in HCM.
Do CMR-derived left atrial strain parameters predict adverse clinical events in patients with hypertrophic cardiomyopathy?
Population
99 patients with HCM and 89 matched control subjects
Comparison
CMR-derived LA strain parameters in HCM patients vs controls and across adverse event status
Design
Cohort study
Follow-up
Mean 37.94 ± 23.69 months
Authors
Loading...
May support CMR LA strain for HCM risk stratification; leaves open prospective validation before clinical adoption.
Do CMR-derived left atrial strain parameters predict adverse clinical events in patients with hypertrophic cardiomyopathy?
CMR-derived left atrial strain assessment, specifically LA GLS booster, provides strong independent predictive value for adverse clinical events in patients with hypertrophic cardiomyopathy.
Tian et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: